arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Cronos Group Inc.

CRON
$3.71 ▲ +0.20 (+5.70%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
8 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cronos Group Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B
Dividend Yield —
Revenue Growth 24.6% ↘
Op. Margin -11.9% ↗
ROIC -0.3% ↗
FCF / Share $0.00 ↘
Trailing P/E —
Price / Book 1.3x
FCF Yield 0.0%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$146.59M
↑ +24.6% —
Net Income Profit after all expenses
$-9.45M
↓ -123.0% —
Operating Margin Operating profit as % of sales
-11.9%
↑ +81.8% 14th
FCF / Share Free cash flow per share
$0.00
↓ -97.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
20
Returns ↑
43
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters